Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing

Action date set for August 22, 2018 STAINES-UPON-THAMES, United Kingdom, Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug ... Biopharmaceuticals, FDA Mallinckrodt, stannsoporfin, hyperbilirubinemia, jaundice
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news